Drug
TAK-659 clinical trials
Also written TAK-659.
A product of Mivavotinib; its studies count on that page too.
- studies test it
- 10
- open now
- 0
- in phase 3
- 0
- first study started
- 2013
How studies write it
Studies that test it under each name
Development codes
- TAK-659
- 10
Studies by the year they started
10 studies that test it; most in 2018 (3)
| Year | Studies |
|---|---|
| 2013 | 1 |
| 2015 | 1 |
| 2016 | 1 |
| 2017 | 2 |
| 2018 | 3 |
| 2019 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 9
- Phase 2
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 9 · Other 1
Calithera Biosciences, Inc (9) · H Scott Boswell (1)
Often tested with
Tested in the same studies.
Venetoclax (1) · Ixazomib (1) · Nivolumab (1) · Bempegaldesleukin (1)
Studies
Open first, then newest update. How each study uses TAK-659 is read from its arms, and is right about nine times in ten.
Testing it · 10
- Study Augmenting TAK-659 Action in Relapsed/Refractory AML by Addition Ofthe Proteasome Inhibitor IxazomibTerminatedPhase 1/2H Scott BoswellNCT04079738Written as TAK-659
- A Study of TAK-659 in Combination With Venetoclax for Adult Participants With Previously Treated Non-Hodgkin LymphomaCompletedPhase 1Calithera Biosciences, IncNCT03357627Written as TAK-659
- A Study of TAK-659 in Adult Participants With Advanced Solid Tumor and Lymphoma MalignanciesCompletedPhase 1Calithera Biosciences, IncNCT02000934Written as TAK-659
- Safety, Tolerability, and Efficacy of TAK-659 in Adults With Relapsed or Refractory Acute Myelogenous Leukemia (AML)TerminatedPhase 1/2Calithera Biosciences, IncNCT02323113Written as TAK-659
- A Study of TAK-659 as a Single Agent in Adult East Asian Participants With Non-Hodgkin Lymphoma (NHL)TerminatedPhase 1Calithera Biosciences, IncNCT03238651Written as TAK-659
- TAK-659 in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)TerminatedPhase 2Calithera Biosciences, IncNCT03123393Written as TAK-659
- A Study of TAK-659 in Combination With Nivolumab in Participants With Advanced Solid TumorsTerminatedPhase 1Calithera Biosciences, IncNCT02834247Written as TAK-659
- A Study to Assess Mass Balance, Pharmacokinetics (PK), and Metabolism of Orally Administered [14 C]-TAK-659 in Participants With Advanced Solid Tumor and/or Lymphoma MalignanciesWithdrawnPhase 1Calithera Biosciences, IncNCT03338881Written as [14C]-TAK-659
- A Study of TAK-659 in Combination With NKTR-214 in Participants With Advanced Non-Hodgkin Lymphoma (NHL)WithdrawnPhase 1Calithera Biosciences, IncNCT03772288Written as TAK-659
- A Study to Evaluate the Effect of Food on the Pharmacokinetics (PK) of TAK-659 in Participants With Advanced Solid TumorWithdrawnPhase 1Calithera Biosciences, IncNCT03359733Written as TAK-659
Given in every arm · 2 — TAK-659 is usual care beside what is tested
- A Study of TAK-659 in Combination With Bendamustine (+/-Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Participants With Advanced Non-Hodgkin LymphomaTerminatedPhase 1Millennium Pharmaceuticals, Inc.NCT02954406Written as TAK-659
- MLN1117 in Combination With Docetaxel, Paclitaxel, and Other Investigational Anticancer Agents to Treat Participants With Gastric and Gastroesophageal AdenocarcinomaTerminatedPhase 1Millennium Pharmaceuticals, Inc.NCT02551055Written as TAK-659